{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:10:43Z","timestamp":1784056243562,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T00:00:00Z","timestamp":1501200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"},{"start":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T00:00:00Z","timestamp":1501200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/bcj.2017.67","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T13:36:32Z","timestamp":1501248992000},"page":"e588-e588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia"],"prefix":"10.1038","volume":"7","author":[{"given":"H-A","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-W","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T-Y","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-8766","authenticated-orcid":false,"given":"XC-H","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W-C","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C-C","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-Y","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C-Y","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-H","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-C","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-L","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-L","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L-I","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H-F","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"key":"BFbcj201767_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fimmu.2012.00020","volume":"3","author":"A Yoshimura","year":"2012","unstructured":"Yoshimura A, Suzuki M, Sakaguchi R, Hanada T, Yasukawa H . SOCS, inflammation, and autoimmunity. Front Immunol 2012; 3: 20.","journal-title":"Front Immunol"},{"key":"BFbcj201767_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cyto.2016.01.005","volume":"82","author":"C Beaurivage","year":"2016","unstructured":"Beaurivage C, Champagne A, Tobelaim WS, Pomerleau V, Menendez A, Saucier C . SOCS1 in cancer: an oncogene and a tumor suppressor. Cytokine 2016; 82: 87\u201394.","journal-title":"Cytokine"},{"key":"BFbcj201767_CR3","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1002\/ijc.27318","volume":"130","author":"J Zhang","year":"2012","unstructured":"Zhang J, Li H, Yu JP, Wang SE, Ren XB . Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer 2012; 130: 1971\u20131980.","journal-title":"Int J Cancer"},{"key":"BFbcj201767_CR4","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1471-2407-10-178","volume":"10","author":"W Sasi","year":"2010","unstructured":"Sasi W, Jiang WG, Sharma A, Mokbel K . Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer 2010; 10: 178.","journal-title":"BMC Cancer"},{"key":"BFbcj201767_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/j.0022-202X.2004.23408.x","volume":"123","author":"Z Li","year":"2004","unstructured":"Li Z, Metze D, Nashan D, Muller-Tidow C, Serve HL, Poremba C et al. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 2004; 123: 737\u2013745.","journal-title":"J Invest Dermatol"},{"key":"BFbcj201767_CR6","first-page":"42","volume":"89","author":"J Roman-Gomez","year":"2004","unstructured":"Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Cervantes F, Barrios M, Colomer D et al. The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica 2004; 89: 42\u201348.","journal-title":"Haematologica"},{"key":"BFbcj201767_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/leu.2013.236","volume":"28","author":"HA Hou","year":"2014","unstructured":"Hou HA, Lin CC, Chou WC, Liu CY, Chen CY, Tang JL et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 2014; 28: 50\u201358.","journal-title":"Leukemia"},{"key":"BFbcj201767_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.leukres.2007.08.010","volume":"32","author":"HA Hou","year":"2008","unstructured":"Hou HA, Chou WC, Lin LI, Tang JL, Tseng MH, Huang CF et al. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 2008; 32: 904\u2013912.","journal-title":"Leuk Res"},{"key":"BFbcj201767_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1182\/blood-2011-07-369934","volume":"119","author":"HA Hou","year":"2012","unstructured":"Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012; 119: 559\u2013568.","journal-title":"Blood"},{"key":"BFbcj201767_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/0165-4608(95)00084-4","volume":"84","author":"HF Tien","year":"1995","unstructured":"Tien HF, Wang CH, Lin MT, Lee FY, Liu MC, Chuang SM et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia: a study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995; 84: 60\u201368.","journal-title":"Cancer Genet Cytogenet"},{"key":"BFbcj201767_CR11","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1158\/0008-5472.CAN-05-4316","volume":"66","author":"WC Chou","year":"2006","unstructured":"Chou WC, Tang JL, Lin LI, Yao M, Tsay W, Chen CY et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006; 66: 3310\u20133316.","journal-title":"Cancer Res"},{"key":"BFbcj201767_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ajh.23611","volume":"89","author":"HA Hou","year":"2014","unstructured":"Hou HA, Kuo YY, Tang JL, Chou WC, Yao M, Lai YJ et al. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. Am J Hematol 2014; 89: 181\u2013186.","journal-title":"Am J Hematol"},{"key":"BFbcj201767_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/sj.leu.2405005","volume":"22","author":"HA Hou","year":"2008","unstructured":"Hou HA, Chou WC, Lin LI, Chen CY, Tang JL, Tseng MH et al. Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3\/ITD. Leukemia 2008; 22: 1075\u20131078.","journal-title":"Leukemia"},{"key":"BFbcj201767_CR14","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1158\/1078-0432.CCR-04-1816","volume":"11","author":"LI Lin","year":"2005","unstructured":"Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005; 11: 1372\u20131379.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201767_CR15","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1182\/blood-2009-05-223784","volume":"114","author":"JL Tang","year":"2009","unstructured":"Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH et al. AML1\/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009; 114: 5352\u20135361.","journal-title":"Blood"},{"key":"BFbcj201767_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","volume":"352","author":"B Falini","year":"2005","unstructured":"Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254\u2013266.","journal-title":"N Engl J Med"},{"key":"BFbcj201767_CR17","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1182\/blood-2009-12-259390","volume":"115","author":"HA Hou","year":"2010","unstructured":"Hou HA, Huang TC, Lin LI, Liu CY, Chen CY, Chou WC et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010; 115: 5222\u20135231.","journal-title":"Blood"},{"key":"BFbcj201767_CR18","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1038\/bcj.2015.59","volume":"5","author":"HA Hou","year":"2015","unstructured":"Hou HA, Chou WC, Kuo YY, Liu CY, Lin LI, Tseng MH et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J 2015; 5: e331.","journal-title":"Blood Cancer J"},{"key":"BFbcj201767_CR19","doi-asserted-by":"publisher","first-page":"9084","DOI":"10.18632\/oncotarget.7000","volume":"7","author":"HA Hou","year":"2016","unstructured":"Hou HA, Liu CY, Kuo YY, Chou WC, Tsai XCH, Lin CC et al. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia. Oncotarget 2016; 7: 9084\u20139101.","journal-title":"Oncotarget"},{"key":"BFbcj201767_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/sj.leu.2402352","volume":"16","author":"HS Shiah","year":"2002","unstructured":"Shiah HS, Kuo YY, Tang JL, Huang SY, Yao M, Tsay W et al. Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. Leukemia 2002; 16: 196\u2013202.","journal-title":"Leukemia"},{"key":"BFbcj201767_CR21","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1182\/blood-2009-11-253070","volume":"115","author":"WC Chou","year":"2010","unstructured":"Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010; 115: 2749\u20132754.","journal-title":"Blood"},{"key":"BFbcj201767_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ajh.23596","volume":"89","author":"CC Lin","year":"2014","unstructured":"Lin CC, Hou HA, Chou WC, Kuo YY, Liu CY, Chen CY et al. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am J Hematol 2014; 89: 137\u2013144.","journal-title":"Am J Hematol"},{"key":"BFbcj201767_CR23","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1182\/blood-2011-02-339747","volume":"118","author":"WC Chou","year":"2011","unstructured":"Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011; 118: 3803\u20133810.","journal-title":"Blood"},{"key":"BFbcj201767_CR24","doi-asserted-by":"publisher","first-page":"641475","DOI":"10.1155\/2015\/641475","volume":"2015","author":"JW Lu","year":"2015","unstructured":"Lu JW, Hsieh MS, Liao HA, Yang YJ, Ho YJ, Lin LI . Zebrafish as a model for the study of human myeloid malignancies. Biomed Res Int 2015; 2015: 641475.","journal-title":"Biomed Res Int"},{"key":"BFbcj201767_CR25","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1038\/leu.2016.132","volume":"30","author":"JW Lu","year":"2016","unstructured":"Lu JW, Hou HA, Hsieh MS, Tien HF, Lin LI . Overexpression of FLT3-ITD driven by spi-1 results in expanded myelopoiesis with leukemic phenotype in zebrafish. Leukemia 2016; 30: 2098\u20132101.","journal-title":"Leukemia"},{"key":"BFbcj201767_CR26","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1182\/blood-2005-01-0179","volume":"106","author":"HF Lin","year":"2005","unstructured":"Lin HF, Traver D, Zhu H, Dooley K, Paw BH, Zon LI et al. Analysis of thrombocyte development in CD41-GFP transgenic zebrafish. Blood 2005; 106: 3803\u20133810.","journal-title":"Blood"},{"key":"BFbcj201767_CR27","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642\u20134649.","journal-title":"J Clin Oncol"},{"key":"BFbcj201767_CR28","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/leu.2016.65","volume":"30","author":"XCH Tsai","year":"2016","unstructured":"Tsai XCH, Hou HA, Tang JL, Liu CY, Lin CC, Chou WC et al. Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. Leukemia 2016; 30: 1485\u20131492.","journal-title":"Leukemia"},{"key":"BFbcj201767_CR29","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1182\/blood-2002-06-1735","volume":"101","author":"O Galm","year":"2003","unstructured":"Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG . SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003; 101: 2784\u20132788.","journal-title":"Blood"},{"key":"BFbcj201767_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/jjco\/hyh035","volume":"34","author":"T Komazaki","year":"2004","unstructured":"Komazaki T, Nagai H, Emi M, Terada Y, Yabe A, Jin E et al. Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK\/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol 2004; 34: 191\u2013194.","journal-title":"Jpn J Clin Oncol"},{"key":"BFbcj201767_CR31","first-page":"5295","volume":"9","author":"O Okochi","year":"2003","unstructured":"Okochi O, Hibi K, Sakai M, Inoue S, Takeda S, Kaneko T et al. Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res 2003; 9: 5295\u20135298.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201767_CR32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1755-148X.2008.00484.x","volume":"21","author":"S Liu","year":"2008","unstructured":"Liu S, Ren S, Howell P, Fodstad O, Riker AI . Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res 2008; 21: 545\u2013558.","journal-title":"Pigment Cell Melanoma Res"},{"key":"BFbcj201767_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/gcc.10222","volume":"37","author":"CY Chen","year":"2003","unstructured":"Chen CY, Tsay W, Tang JL, Shen HL, Lin SW, Huang SY et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer 2003; 37: 300\u2013305.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFbcj201767_CR34","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1365-2141.2004.05107.x","volume":"126","author":"D Watanabe","year":"2004","unstructured":"Watanabe D, Ezoe S, Fujimoto M, Kimura A, Saito Y, Nagai H et al. Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol 2004; 126: 726\u2013735.","journal-title":"Br J Haematol"},{"key":"BFbcj201767_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ng0501-29","volume":"28","author":"H Yoshikawa","year":"2001","unstructured":"Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE et al. SOCS-1, a negative regulator of the JAK\/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 29\u201335.","journal-title":"Nat Genet"},{"key":"BFbcj201767_CR36","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1182\/blood-2010-08-301416","volume":"120","author":"PN Reddy","year":"2012","unstructured":"Reddy PN, Sargin B, Choudhary C, Stein S, Grez M, Muller-Tidow C et al. SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control. Blood 2012; 120: 1691\u20131702.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201767.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201767","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bcj.2017.67","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201767.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:02:04Z","timestamp":1784055724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,28]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"alternative-id":["BFbcj201767"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2017.67","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,28]]},"assertion":[{"value":"29 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}